Literature DB >> 15939066

Prevalence of insulin resistance and the metabolic syndrome with alternative definitions of impaired fasting glucose.

Earl S Ford1, Fahim Abbasi, Gerald M Reaven.   

Abstract

We sought to evaluate the effect of the new definition of impaired fasting glucose (IFG = fasting glucose concentration 100-125 mg/dL among people without diabetes) on the ability to identify insulin resistance, as well as the prevalence of the metabolic syndrome in apparently healthy individuals. From the Stanford General Clinical Research Center data-base, we used data from 230 men and 260 women aged 19-79 years who had had an insulin suppression test to measure insulin resistance. From the Third National Health and Nutrition Examination Survey (1988-1994), we used data from 8814 participants aged > or =20 years to estimate the impact of adopting the new IFG criteria on the prevalence of the metabolic syndrome. Among the 490 participants, the prevalence of IFG increased from 5.5% under the old definition of IFG to 20.4% under the new definition. Using the old definition of IFG, the sensitivity, specificity, and positive predictive value (PPV) of IFG of identifying an individual as being insulin resistant were 10%, 97%, and 63%, respectively. Using the new definition, these parameters were 33%, 88%, and 61%, respectively. If the new IFG criteria were adopted, the prevalence of the metabolic syndrome would increase from 21.8% to 26.3%. The new definition of IFG expands the population with insulin resistance by almost four-fold and could expand the population with the metabolic syndrome by about 20%. The clinical and public health implications of the new IFG definition remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939066     DOI: 10.1016/j.atherosclerosis.2005.01.002

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  The myth of the metabolic syndrome.

Authors:  Edwin A M Gale
Journal:  Diabetologia       Date:  2005-07-16       Impact factor: 10.122

2.  Occurrence of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome in patients with abdominal obesity. Where is a sufficient level of testosterone?

Authors:  Juraj Fillo; Jan Breza; Michaela Levčíkova; Jan Luha; Anna Vachulova; Štefan Durdík; Peter Labaš
Journal:  Int Urol Nephrol       Date:  2012-08       Impact factor: 2.370

3.  Association of surrogate and direct measures of adiposity with risk of metabolic syndrome in rural Chinese women.

Authors:  Fengxiu Ouyang; Jonathan Necheles; Binyan Wang; Wei Ma; Zhiping Li; Xue Liu; Genfu Tang; Houxun Xing; Xiping Xu; Scott A Venners; Wendy J Brickman; Katherine Kaufer Christoffel; Donald Zimmerman; Xiaobin Wang
Journal:  Eur J Nutr       Date:  2009-04-01       Impact factor: 5.614

4.  Identification and Management of Cardiometabolic Risk after Spinal Cord Injury.

Authors:  Mark S Nash; Suzanne L Groah; David R Gater; Trevor A Dyson-Hudson; Jesse A Lieberman; Jonathan Myers; Sunil Sabharwal; Allen J Taylor
Journal:  J Spinal Cord Med       Date:  2019-06-10       Impact factor: 1.985

5.  Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers.

Authors:  Mark S Nash; Suzanne L Groah; David R Gater; Trevor A Dyson-Hudson; Jesse A Lieberman; Jonathan Myers; Sunil Sabharwal; Allen J Taylor
Journal:  Top Spinal Cord Inj Rehabil       Date:  2018

Review 6.  Adipose tissue dysfunction and its effects on tumor metabolism.

Authors:  Jonathan Diedrich; Halina Chkourko Gusky; Izabela Podgorski
Journal:  Horm Mol Biol Clin Investig       Date:  2015-01

7.  Racial differences in risk of prostate cancer associated with metabolic syndrome.

Authors:  Jennifer L Beebe-Dimmer; Nora L Nock; Christine Neslund-Dudas; Andrew Rundle; Cathryn H Bock; Deliang Tang; Michelle Jankowski; Benjamin A Rybicki
Journal:  Urology       Date:  2009-05-09       Impact factor: 2.649

8.  Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study.

Authors:  M Deuschle; F Paul; M Brosz; N Bergemann; M Franz; J Kammerer-Ciernioch; M Lautenschlager; F Lederbogen; D Roesch-Ely; M Weisbrod; K G Kahl; J Reichmann; J Gross; J Umbreit
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-03-21       Impact factor: 4.328

9.  Postprandial insulin resistance as an early predictor of cardiovascular risk.

Authors:  W Wayne Lautt
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.